October 6, 2015
An investigational drug-eluting peripheral vascular stent was safe and effective at 12 months, according to findings presented at the Cardiovascular and Interventional Radiological Society of Europe annual meeting.
Researchers conducted the prospective, single-arm MAJESTIC trial of the peripheral vascular paclitaxel-eluting stent (Eluvia, Boston Scientific) in 57 patients with femoropopliteal artery lesions. The mean age of patients was 69 years and 83% were men. Mean lesion length was 70.8 mm, 46% of lesions were classified as total occlusions and 65% were identified as severely calcified, according to a press release.